Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NEPH NASDAQ:OSRH NASDAQ:STRR NASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNEPHNephros$3.78+0.5%$3.45$2.66▼$6.42$40.82M1.498,803 shs8,068 shsOSRHOSR$0.47-3.8%$0.42$0.30▼$1.24$17.05M0.72734,725 shs1.15 million shsSTRRStar Equity$11.16+0.1%$11.02$8.38▼$11.99$41.21M0.513,632 shs4,524 shsTELATELA Bio$0.73-2.6%$0.85$0.50▼$2.19$33.60M1.3484,911 shs17,447 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNEPHNephros+0.53%+4.13%+18.13%+28.14%+9.57%OSRHOSR-3.79%+42.27%+21.60%-18.04%-55.50%STRRStar Equity+0.09%-2.15%+0.72%+15.95%+466.50%TELATELA Bio-2.61%-13.70%-14.91%+7.06%-63.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNEPHNephros$3.78+0.5%$3.45$2.66▼$6.42$40.82M1.498,803 shs8,068 shsOSRHOSR$0.47-3.8%$0.42$0.30▼$1.24$17.05M0.72734,725 shs1.15 million shsSTRRStar Equity$11.16+0.1%$11.02$8.38▼$11.99$41.21M0.513,632 shs4,524 shsTELATELA Bio$0.73-2.6%$0.85$0.50▼$2.19$33.60M1.3484,911 shs17,447 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNEPHNephros+0.53%+4.13%+18.13%+28.14%+9.57%OSRHOSR-3.79%+42.27%+21.60%-18.04%-55.50%STRRStar Equity+0.09%-2.15%+0.72%+15.95%+466.50%TELATELA Bio-2.61%-13.70%-14.91%+7.06%-63.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNEPHNephros 2.33Hold$5.0032.28% UpsideOSRHOSR 1.00SellN/AN/ASTRRStar Equity 2.20Hold$28.00150.90% UpsideTELATELA Bio 2.40Hold$2.20200.96% UpsideCurrent Analyst Ratings BreakdownLatest OSRH, STRR, NEPH, and TELA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026NEPHNephros Northland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$4.006/24/2026OSRHOSR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/18/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)6/4/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/21/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/20/2026STRRStar Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/20/2026STRRStar Equity Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/7/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/6/2026STRRStar Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)4/21/2026TELATELA Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNEPHNephros$18.79M2.18$0.13 per share29.98$0.96 per share3.94OSRHOSR$2.91M5.64N/AN/A$4.95 per share0.09STRRStar Equity$172.16M0.24$0.63 per share17.60$19.12 per share0.58TELATELA Bio$80.28M0.41N/AN/A$0.16 per share4.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNEPHNephros$1.19M$0.0754.01N/AN/A4.06%7.66%5.86%8/6/2026 (Estimated)OSRHOSR-$27.06M-$0.33N/AN/AN/A-363.26%-7.24%-5.41%N/ASTRRStar Equity-$5.92M-$2.63N/A10.73N/A-4.18%-4.04%-2.40%8/6/2026 (Estimated)TELATELA Bio-$38.83M-$0.79N/AN/AN/A-49.30%-1,320.81%-55.83%8/10/2026 (Estimated)Latest OSRH, STRR, NEPH, and TELA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026TELATELA Bio-$0.17N/AN/AN/A$20.01 millionN/A8/6/2026Q2 2026NEPHNephros-$0.0050N/AN/AN/A$5.05 millionN/A8/6/2026N/ASTRRStar Equity-$0.07N/AN/AN/A$56.92 millionN/A5/13/2026Q1 2026OSRHOSRN/A-$0.09N/A-$0.0880N/A$0.48 million5/12/2026Q1 2026TELATELA Bio-$0.14-$0.21-$0.07-$0.21$18.60 million$19.06 million5/11/2026Q1 2026STRRStar Equity$0.05-$0.99-$1.04-$1.17$52.57 million$50.06 million5/7/2026Q1 2026NEPHNephros$0.01$0.01N/A$0.01$5.02 million$5.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNEPHNephrosN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/ASTRRStar EquityN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNEPHNephrosN/A4.553.12OSRHOSRN/A0.160.14STRRStar Equity0.092.091.84TELATELA Bio8.823.612.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNEPHNephros41.10%OSRHOSR55.30%STRRStar Equity3.84%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipNEPHNephros6.70%OSRHOSR36.80%STRRStar Equity31.60%TELATELA Bio5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNEPHNephros3010.86 million10.13 millionNot OptionableOSRHOSRN/A35.10 million22.19 millionN/ASTRRStar Equity1,2003.70 million2.53 millionNot OptionableTELATELA Bio12044.77 million42.48 millionOptionableOSRH, STRR, NEPH, and TELA HeadlinesRecent News About These CompaniesA perfect matchJuly 16 at 9:09 AM | bbc.comBTELA Bio Healthcare Story Faces New Market ScrutinyMay 15, 2026 | kalkinemedia.comKEarnings Release: Here's Why Analysts Cut Their TELA Bio, Inc. (NASDAQ:TELA) Price Target To US$2.25May 15, 2026 | finance.yahoo.comTELA Bio Inc (TELA) Q1 2026 Earnings Call Highlights: Strong European Growth and Strategic U.S. ...May 13, 2026 | finance.yahoo.comTELA Bio, Inc. (TELA) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comTELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue EstimatesMay 12, 2026 | zacks.comTELA Bio Reports First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comWhat To Expect From TELA Bio Inc (TELA) Q1 2026 EarningsMay 11, 2026 | finance.yahoo.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 | globenewswire.comAxos, Gallagher and TELA Bio post strong growth and strategic movesMay 1, 2026 | msn.comTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports ...April 30, 2026 | markets.businessinsider.comTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesApril 30, 2026 | globenewswire.comTELA Bio (TELA) Gets a Buy from Canaccord GenuityApril 26, 2026 | theglobeandmail.comTELA Bio to Announce First Quarter 2026 Financial ResultsApril 21, 2026 | globenewswire.comTELA Bio (TELA) price target decreased by 34.78% to 2.30April 10, 2026 | msn.comTELA Bio, Inc. Q4 2025 Earnings Call SummaryMarch 26, 2026 | finance.yahoo.comTELA Bio, Inc.: TELA Bio Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 26, 2026 | finanznachrichten.deTELA Bio (TELA) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | finance.yahoo.comTELA Bio Q4 Earnings Call HighlightsMarch 26, 2026 | defenseworld.netDTELA Bio Analysts Cut Their Forecasts After Q4 ResultsMarch 25, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026SK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Micron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 20263 Biotech Firms With Major Potential Catalysts in the Coming MonthsBy Nathan Reiff | June 21, 2026OSRH, STRR, NEPH, and TELA Company DescriptionsNephros NASDAQ:NEPH$3.78 +0.02 (+0.53%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$3.72 -0.06 (-1.59%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.OSR NASDAQ:OSRH$0.47 -0.02 (-3.79%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$0.47 +0.00 (+0.60%) As of 07/17/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Star Equity NASDAQ:STRR$11.16 +0.01 (+0.09%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$11.29 +0.13 (+1.16%) As of 07/17/2026 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Star Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.TELA Bio NASDAQ:TELA$0.73 -0.02 (-2.61%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$0.74 +0.01 (+1.64%) As of 07/17/2026 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/13- 07/17 The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
